论文部分内容阅读
目的:分析研究尿激酶对急性心肌梗死的临床治疗效果。方法:回顾性分析2013年6月至2014年6月期间在我院治疗的90例急性心肌梗死患者的临床资料。90例患者随机分为观察组和对照组各45例,对照组给予常规方法进行治疗,观察组在对照组的基础上使用尿激酶静脉溶栓治疗,观察2组临床疗效及不良反应。结果:观察组治疗总有效率(95.55%)明显高于对照组治疗总有效率(86.66%),组间比较差异显著(P<0.05);观察组的再通率(68.89%)显著高于对照组(24.44%),组间比较差异显著(P<0.05)。结论:尿激酶静脉溶栓治疗急性心肌梗患者能有效地提高血管再通率,疗效显著且安全性高,值得临床上使用。
Objective: To analyze the clinical effect of urokinase on acute myocardial infarction. Methods: The clinical data of 90 patients with acute myocardial infarction treated in our hospital from June 2013 to June 2014 were retrospectively analyzed. Ninety patients were randomly divided into observation group and control group, 45 cases in each group. The control group was treated by conventional method. The observation group was treated with intravenous thrombolysis of urokinase on the basis of the control group. The clinical efficacy and adverse reactions in the two groups were observed. Results: The total effective rate (95.55%) in the observation group was significantly higher than that in the control group (86.66%), the difference between the two groups was significant (P <0.05); the recanalization rate (68.89%) in the observation group was significantly higher than that The control group (24.44%), the difference between the groups was significant (P <0.05). Conclusion: Intravenous thrombolysis of urokinase in patients with acute myocardial infarction can effectively improve the rate of recanalization, with significant curative effect and high safety. It is worth to be used clinically.